Frontiers in Pediatrics · 6 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective study assessed regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) in 23 neonates over 57 sessions. The central result was that RCA was found to be safe and effective, with a filter life of 31.54 ± 19.58 hours and no significant increase in citrate accumulation incidence post-treatment.
This retrospective observational study reviewed 57 sessions of RCA-CRRT performed on 23 neonates in a pediatric ICU. The mean filter life was 31.54 ± 19.58 hours. There was no statistically significant increase in the total-to-ionized calcium ratio (T/iCa) or the incidence of citrate accumulation (T/iCa >2.5) from pre- to post-treatment. In a subgroup analysis, the citrate accumulation group had a significantly higher body weight and lower blood flow rate per body weight, but no significant differences were found in age or corrected gestational age. The study concluded that RCA-CRRT is safe and effective for neonates, and the incidence of citrate accumulation was not higher than in children or adults. Limitations include the retrospective design and small sample size.
